Abstract
In recent years, the use of boosted protease inhibitors monotherapy has become increasingly important, especially considering the advantages in terms of costs, tolerability, and simplification. Despite that, knowledge about the efficacy and safety of this approach in HIV-1-infected adolescents who have acquired HIV-1 infection through perinatal transmission is still limited. We report here our experience with two adolescents who have been successfully treated with lopinavir/ritonavir monotherapy.
Publication types
-
Case Reports
-
Comparative Study
MeSH terms
-
Adolescent
-
Adult
-
Female
-
HIV Infections / drug therapy*
-
HIV Infections / transmission*
-
HIV Infections / virology
-
HIV Protease Inhibitors / therapeutic use*
-
HIV-1 / drug effects*
-
HIV-1 / genetics
-
Humans
-
Infectious Disease Transmission, Vertical / prevention & control*
-
Lopinavir / therapeutic use*
-
Male
-
RNA, Viral / genetics
-
Ritonavir / therapeutic use*
-
Treatment Outcome
-
Viral Load
-
Young Adult
Substances
-
HIV Protease Inhibitors
-
RNA, Viral
-
Lopinavir
-
Ritonavir